PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	
	)	
BOCK et al.	)	Art Unit: Unassigned
	)	
Application No. 10/516,662	)	Examiner: Unassigned
	)	
Filing Date: June 2, 2003	)	Confirmation No. 2888
	)	
For: VARIANTS OF ANTITHROMBIN III	)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 CFR 1.98 (a)(2), copies of any cited U.S. Patent or U.S. Patent Publication documents are not enclosed.

In accordance with the provisions of M.P.E.P. § 2001.06(b) and 37 C.F.R. § 1.98(b)(3), Applicants would like to bring to the attention of the Examiner the existence of the co-pending patent application(s) identified below, which were filed in the United States Patent and Trademark Office:

Application No.	Date Filed	Inventors	Attorney Docket No.
PCT/US05/00843	January 10/2005	Bock et al.	21101.0054P1

In accordance with the requirements of 37 C.F.R. § 1.98(a)(2)(iii), a copy of the above-referenced application specification(s), including the claims and drawings thereof, is enclosed.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Christopher L. Curfman, JD, PhD
Registration No. 52,787

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Christopher L. Curfman

11/23/05
Date

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/516,662
Filing Date	June 2, 2003
First Named Inventor	Bock *et al.*
Group Art Unit	Unassigned
Examiner Name	Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate
	A1	6,878,813	04/12/05	Bock et al.	530	393	12/11/01
	A2	5,204,253	04/20/93	Sanford et al.	435	459	
	A3	5,420,252	05/30/95	Kato et al.	530	393	
	A4	5,618,713	04/08/97	Zettlemeissl et al.	435	226	
	A5	5,700,663	12/23/97	Zettlemeissl et al.	435	69.6	
	A6	5,843,705	12/01/98	DiTullio et al.	800	7	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	A7	EP 0 568 833 A1	08/04/93	Kato et al.	
	A8	WO 90/09737	07/09/90	Blood Research Center	
	A9	WO 91/00291	01/10/91	Akzo	
	A10	WO 95/05853	03/02/95	Carson et al.	

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	A11	Backovic and Gettins, "Insight into residues critical for antithrombin function from an expanded database of sequences that includes frog, turtle and ostrich antithrombins." J. Proteome Res. **2002** 1:367-373.
	A12	Bayston et al. "Familial overexpression of beta antithrombin caused by an Asn135Thr substitution." Blood **1999** 93:4242-7.
	A13	Bick et al. "Antithrombin III patterns in disseminated intravascular coagulation." Am. J. Clin. Pathol. **1980** 73(4):577-83.
	A14	Blauhut et al. "Substitution of antithrombin III in shock and DIC: a randomized study." Thromb. Res. **1985** 39(1):81-9.
	A15	Bock et al., "Cleaved and inactivated antithrombin III in bronchoalveolar lavage (BAL) samples from acute respiratory distress (ARDS) and at-risk for ARDS patents," Proteases/Antiproteases, seminar, Amer. J. Respir. Crit. Care Med., **2001**, A63. (Poster Abstract)
	A16	Bock et al. "Cloning and expression of the cDNA for human antithrombin III." Nucleic Acids Res. **1982** 10(24):8113-25.
	A17	Brennan et al. "Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135." FEBS Lett. **1987** 219(2):431-6.
	A18	Buller and Cate, "Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate." Am. J. Med. **1989** 87(3B):44S-48S.
	A19	Carlson et al. "Comparison of the behavior in vivo of two molecular forms of antithrombin III." Biochem. J. **1985** 225:557-64.
	A20	Carrell and Owen, "Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis." Nature. **1985** 317(6039):730-2.
	A21	Cohen et al. "In vivo inactivation of antithrombin III is promoted by heparin during cardiopulmonary bypass." J. Invest. Surg. **1992** 5:45-9.
	A22	Cunningham et al. "Development of an elastase-resistant antithrombin through mutagenesis at P4." Blood. **1995** 86(10 Supp.):375A. (Abstract)

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/516,662
	Filing Date	June 2, 2003
	First Named Inventor	Bock *et al.*
	Group Art Unit	Unassigned
	Examiner Name	Unassigned

	A23	Cunningham et al. "Impact of mutations at the P4 and P5 position on the reation of antithrombin with thrombin and elastase." Thromb. Res. **1997** 88(2):171-81.
	A24	Damus and Wallace, "Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy." Thromb Res. **1975** 6(1):27-38.
	A25	deAgostini et al. "Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta." J. Cell Biol. **1990** 111:1293-1304.
	A26	Delsharnmar et al. "Abnormal proteolysis (DIC)--successful treatment with antithrombin III concentrate and a concentrate containing F XIII and native von Willebrand factor." J. Intern. Med. **1989** 225(1):21-7.
	A27	Dickneite and Paques, "Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis." Thromb Haemost. **1993** 69(2):98-102.
	A28	Dunzendorfer et al. "Cell-surface heparan sulfate proteoglycanmediatedregulation of human neutrophil migration by the serpin antithrombin III." Blood **2001** 97:1079-85.
	A29	Emerson et al. "Efficacy of antithrombin III supplemtation in animal models of fulminant Eschericia coli endotoxemia or bacteremia." Am. J. Med. **1989** 87:27S-33S.
	A30	Emerson et al. "Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat." Circ Shock. **1987** 21(1):1-13.
	A31	Ersdal-Badju et al. "Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirusinfected insect cells." Biochem. J. **1995** 310:323-30.
	A32	Fourrier et al. "Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation." Chest. **1993** 104(3):882-8.
	A33	Franzen et al. "Structural studies on the carbohydrate portion of human antithrombin III." J. Biol. Chem. **1980** 255(11):5090-3.
	A34	Frebelius et al. "Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT-beta." Thromb. Vasc. Biol. **1996** 16:1292-7.
	A35	Hedin et al. "Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells." Arterioscler Thromb. **1994** 14(2):254-60.
	A36	Hellgren et al. "Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients." Thromb Res. **1984** 35(4):459-66.
	A37	Hellgren et al. "Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients." Intensive Care Med. **1984** 10(1):23-8.
	A38	Hoffmann et al. "Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium." Crit. Care Med. **2002** 30:218-25.
	A39	Ishiguro, K. et al. "Complete antithrombin deficiency in mice results in embryonic lethality." J. Clin. Invest. **2000** 106(7):873-878.
	A40	Jairajpuri et al. "Elimination of P1 arginine-393 interaction with underlying glutamic acid-255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition." J. Biol. Chem. **2002** 277:24460-5.
	A41	Jochum et al. "Effect of human granulocytic elastase on isolated human antithrombin III." Hoppe Seylers Z Physiol Chem. **1981** 362(2):103-12.
	A42	Jochum, "Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation." Semin Hematol. **1995** 32(4 Suppl 2):19-32.
	A43	Jordan et al. "Heparin promotes the inactivation of antithrombin by neutrophil elastase." Science. **1987** 237(4816):777-9.

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/516,662
	Filing Date	June 2, 2003
	First Named Inventor	Bock *et al.*
	Group Art Unit	Unassigned
	Examiner Name	Unassigned

	A44	Jordan, "Antithrombin in vertebrate species: conservation of the heparin-dependent anticoagulant mechanism." Arch. Biochem. Biophys. **1983** 227(2):587-95.
	A45	Kato et al. "Recombinant antithrombin III mutations with enhanced antithrombin activity without heparin." 69th Scientific Sessions, Abstract 4336, **1996** 94:8 Supp., p. I-741. (Abstract)
	A46	Kocsis et al. "Heparin-coated stents." J. Long-Term Effects of Medical Implants. **2000** 10:19-45.
	A47	Kurachi et al. "Inhibition of bovine factor IXa and factor Xabeta by antithrombin III." Biochemistry. **1976** 15(2):373-7.
	A48	Lammle et al. "Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC)." Am. J. Clin. Pathol. **1984** 82(4):396-404.
	A49	Lawson et al. "Complex-dependent inhibition of factor VIIa by antithrombin III and heparin." J. Biol. Chem. **1993** 268(2):767-70.
	A50	Mammen et al. "Human antithrombin concentrates and experimental disseminated intravascular coagulation." Semin. Thromb. Hemost. **1985** 11(4):373-83.
	A51	Mant et al. "Haemorrhagic complications of heparin therapy." Lancet. **1977** 1(8022):1133-5.
	A52	Marcum et al. "Microvascular heparin-like species with anticoagulant activity." Am. J. Physiol. **1983** 245(5 Pt 1):H725-33.
	A53	Minnema et al. "Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli." Blood. **2000** 95(4):1117-23.
	A54	Mizuochi et al. "Structural studies of the carbohydrate moiety of human antithrombin III." Arch. Biochem. Biophys. **1980** 203(1):458-65.
	A55	Nakajima et al., "Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase," J. Biol. Chem. **1979** 254:4027.
	A56	Nuijens et al. "Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis." J. Lab. Clin. Med. **1992** 119(2):159-68.
	A57	O'Reilley et al. "Antiangiogenic activity of the cleaved conformation of the serpin antithrombin." Science. **1999** 285(5435):1926-8.
	A58	Oelschläger et al. "Antithrombin III inhibits nuclear factor kappa B activation in human monocytes and vascular endothelial cells." Blood **2002** 99:4015-20.
	A59	Olson et al. "Identification of critical molecular interactions mediating heparin activation of antithrombin. Implications for the design of improved heparin anticoagulants." Trends Cardiovasc. Med. **2002** 12:198-205.
	A60	Olson et al. "Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement." J. Biol. Chem. **1992** 267(18):12528-38.
	A61	Ostrovsky et al. "Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion." Circulation. **1997** 96(7):2302-10.
	A62	Owen et al." P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase. Implications for the heparin activation mechanism." FEBS Lett. **1991** 280(2):216-20.
	A63	Petersen et al., Primary structure of antithrombin III (heparin cofactor) – partial homology between α1-antitrypsin and antithrombin-III." The Physiological Inhibitors of Coagulation and Fibrinolysis, Elsevier/North Holland Biomedical Press. **1979** pp. 43-54.
	A64	Peterson and Blackburn, "Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding." J. Biol. Chem. **1985** 260(1):610-5.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/516,662
	Filing Date	June 2, 2003
	First Named Inventor	Bock *et al.*
	Group Art Unit	Unassigned
	Examiner Name	Unassigned

	A65	Picard and Bock, "Rapid and efficient one-tube PCR-based mutagenesis method." Methods in Mol. Biol. Vol. 67, PCR Cloning Protocols. From moluclar cloning to genetic engineering. B.A. White Humana Press, Totowa, NJ, **1996**, 183-8.
	A66	Picard et al. "A rapid and efficient one-tube PCR-based mutagenesis technique using Pfu DNA polymerase." Nucleic Acid Res. **1994** 22(13):2587-91.
	A67	Picard et al. "Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity." Biochemistry. **1995** 34(26):8433-40.
	A68	Rao et al. "Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa." Blood. **1993** 81(10):2600-7.
	A69	Rosenberg and Damus, "The purification and mechanism of action of human antithrombin-heparin cofactor." J. Biol. Chem. **1973** 248(18):6490-505.
	A70	Rosenberg, "Chemistry of the hemostatic mechanism and its relationship to the action of heparin." Fed. Proc. **1977** 36(1):10-8.
	A71	Rothenburger et al. "Treatment of thrombus formation associated with theMicroMed DeBakey VAD using recombinant tissue plasminogen activator." Circulation **2002** 106(suppl I): I-189-92.
	A72	Ruf and Mueller, "Tissue factor in cancer angiogenesis and metastasis." Curr. Opin. Hematol. **1996** 3(5):379-84.
	A73	Seitz et al. "Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections." Eur. J. Haematol. **1987** 38(3):231-40.
	A74	Stephens et al. "Site directed mutagenesis of the reactive center (serine 394) of antithrombin III." J. Biol. Chem. **1988** 263(31):15849-52.
	A75	Tani et al. "Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis." Am. J. Respir. Cell Mol. Biol. **1991** 5(1):34-40.
	A76	Tejada, M.L. and Deeley, R.G. "Cloning of an avian antithrombin: developmental and hormonal regulation of expression." Thromb. Haemost. **1995** 73(4):654-661.
	A77	Turk et al. "The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change." Biochemistry. **1997** 36(22):6682-91.
	A78	Uchiba et al. "Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III." Semin. Thromb. Hemost. **1997** 23(6):583-90.
	A79	van Boven and Lane, "Antithrombin and its inherited deficiency states." Semin. Hematol. **1997** 34(3):188-204.
	A80	Varga et al. "Infectious entry pathway of adenovirus type 2." J. Virol. **1991** 65(11):6061-70.
	A81	Vinazzer, "Antithrombin III in shock and disseminated intravascular coagulation." Clin. Appl. Thrombosis/Hemostasis. **1995** 1:62-5.
	A82	Warren et al. "High-dose antithrombin III in severe sepsis: a randomized controlled trial." JAMA. **2001** 286(15):1869-78.
	A83	Witmer and Hatton, "Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelialized aortic wall in vitro and in vivo." Arteriosclerosis and Thrombosis. **1991** 11:530-9.
	A84	Wolff et al. "Direct gene transfer into mouse muscle in vivo." Science. **1990** 247(4949 Pt 1):1465-8.
	A85	Zendehrouh, Ph.D. Dissertation, "Novel proteinase inhibitors for use in treatment of sepsis." Temple Univ. School of Medicine, publically available at the Univeristy of Michigan dissertation archive in **1999**.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	